UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink’s Biometrics Data Platform. The study, consisting of 70 patients, will evaluate if regimented moderate intensity exercise improves overall exercise capacity and cardiac blood flow.
HCM is thought to be the most common inherited heart condition, estimated to affect about 1 in 500 people, can lead to heart failure and atrial fibrillation, and is cited as the most common cause of sudden death in young athletes, accounting for 35 to 50 percent of cases. The UCSF study, EXCITE-HCM, is funded by the National Heart Lung and Blood Institute of the National Institutes of Health, and led by Theodore Abraham, MD, FACC, FASE.
“In this study, we hope to identify ways to prevent adverse health events for these patients,” said Theodore Abraham, MD, FACC, FASE, co-director of UCSF HCM Center of Excellence, and Director of the UCSF Adult Cardiac Echocardiography Laboratory.
Subjects in the research trial will be monitored using the Vivalink wearable ECG sensor and cloud data platform to track electrical activity throughout the study. The reusable sensor will continually capture ECG and heart rate data 24 hours a day, which will be processed through Vivalink’s Biometrics Data Platform.